Clinical trials: Renal Tumor
Neuroendocrine Tumors, Liver Metastases
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with…
- Trial name
- ILUMINET (NCT01456078)
- Testing
- 177Lu-DOTA-TATE
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Lund University Hospital
Advanced Renal Cell Carcinoma
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and…
- Trial name
- ARCITECT (NCT05928806)
- Testing
- Botensilimab, Balstilimab, Ipilimumab
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Michael B. Atkins, MD
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Liver Neoplasm, Kidney Injury, Acute
Perioperative Myocardial and Renal Injury in Patients Undergoing Hepatic Resection
Liver surgeries are high risk surgeries that might result in injuries in kidneys and heart. This study was planned to investigate the frequency of these injuries as well as the risk factors for their devolopment and its effect on…
- Conditions
- Liver Neoplasm, Kidney Injury, Acute, Myocardial Injury After Non-Cardiac Surgery
- Trial name
- NCT06775158
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Istanbul Saglik Bilimleri University
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes, Chronic Kidney Diseases
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop…
- Conditions
- Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease
- Trial name
- BRANCH-P (NCT05473325)
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Willows Health
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Carcinoma, Renal Cell
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
There are two primary aims in the study: 1) to determine the tolerability and feasibility of combination hypofractionated radiation therapy and PD-1 inhibition with nivolumab, and 2) to determine the ability of hypofractionated…
- Trial name
- NCT02962804
- Testing
- Nivolumab, Radiation
- Where
- United States
- Sponsor
- University of Kansas Medical Center
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell…
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT01282333
- Testing
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
EBV Infection, EBV Viremia
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Transplant recipients are treated with immunosuppressive drugs to avoid rejection of the transplanted organ. As the medication impairs the immune response, it also increases the risk of serious infections and cancer in transplant…
- Conditions
- EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
- Trial name
- EVITA (NCT04189835)
- Testing
- EBV DNA in whole blood and plasma
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 509 people
- Sponsor
- University of Aarhus
Renal Clear Cell Carcinoma, HIF-2α
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
This project aims to conduct a multicenter retrospective study to collect clinical, CT imaging, and pathological data from patients.
- Conditions
- Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram
- Trial name
- NCT07332923
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Cardiac Disease, Cancer
Electronic Medical Records and Genomics (eMERGE) Phase III
The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes.
- Conditions
- Cardiac Disease, Cancer, Hypercholesterolemia, Diabetes
- Trial name
- eMERGE (NCT03394859)
- Volunteers
- 25,380 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Stroke, Osteoporosis
Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases
The objective of this study is to investigate the effects of therapeutic exercise and nutrition intervention for sarcopenia and risk of falls in patients with major chronic diseases.
- Conditions
- Stroke, Osteoporosis, Chronic Kidney Diseases, Cancer
- Trial name
- NCT03798418
- Testing
- elastic band strengthening exercise, diet counseling
- Where
- Taiwan
- Volunteers
- 186 people
- Sponsor
- Changhua Christian Hospital
Renal Cell Cancer
Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
This study is a phase 2, multicenter, interventional for cohort 1 \& 2, non-interventional for cohort 3, open-label trial of cabozantinib, with ORR as the primary efficacy endpoint.
- Trial name
- NCT04714697
- Testing
- Cabometyx
- Where
- South Korea
- Volunteers
- 201 people
- Sponsor
- Asan Medical Center
Renal Carcinoma Metastatic, Kidney Neoplasms
Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma
Physician mainly use RECIST progression-free survival (PFS) and NCI CTCAE safety as a guide to evaluate treatment efficiency. In contrast Health Related Quality of Life (HRQOL) assessment is often restricted to clinical trial.
- Conditions
- Renal Carcinoma Metastatic, Kidney Neoplasms, Renal Cancer
- Trial name
- QUANARIE (NCT03062410)
- Testing
- Electronic PRO in daily clinical practice
- Where
- 8 sites in France
- Volunteers
- 56 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Transplantation
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
This study intends to determine whether steroid withdrawal or calcineurin inhibitor withdrawal is superior for graft function and graft survival.
- Trial name
- CISTCERT (NCT00903188)
- Testing
- cyclosporine, Everolimus
- Where
- 5 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- University Hospital, Antwerp
Upper Tract Urothelial Carcinoma
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)
The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously…
- Trial name
- NCT03617003
- Testing
- WST11 mediated vascular targeted phototherapy (VTP), Endoscopy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Tumor
Irreversible Electroporation(IRE) For Unresectable Renal Tumors
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation (IRE) for unresectable renal tumors.
- Trial name
- IRE (NCT02335827)
- Testing
- irreversible electroporation
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou